Rights Issue

Sprint Bioscience

November 18, 2022

Sector

Healthcare

Transaction

Naventus has advised Sprint Bioscience on its Rights Issue of SEK 22,4 million.

all transactions
Sprint Bioscience

Contact us

Would you like to know more about our Corporate Finance services?
Contact our dedicated team.

CORPORATE FINANCE TEAM
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.